Meeting
2014 ASCO Annual Meeting
Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.
Authors
Steven E. Coutre
Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA
Steven E. Coutre , Richard R. Furman , Jeff Porter Sharman , Bruce D. Cheson , John M. Pagel , Peter Hillmen , Jacqueline Claudia Barrientos , Andrew David Zelenetz , Thomas J. Kipps , Ian Flinn , Paolo Ghia , Herbert Aaron Eradat , Thomas J. Ervin , Nicole Lamanna , Bertrand Coiffier , Andrew Pettitt , Yeonhee Kim , Thomas Michael Jahn , Susan Mary O'Brien , Michael J. Hallek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT01539512
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7012)
DOI
10.1200/jco.2014.32.15_suppl.7012
Abstract #
7012
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.
First Author: Wojciech Jurczak
Poster
2017 ASCO Annual Meeting
Ironclad: A randomized phase III study of ibrutinib (Ibr) or no consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL).
First Author: Charalambos Andreadis
Poster
2016 ASCO Annual Meeting
Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).
First Author: Jeffrey Alan Jones
Poster
2015 ASCO Annual Meeting
Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation.
First Author: Jacqueline Claudia Barrientos